CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. He J, Lan X, Liu X, Deng C, et al. BMC Cancer 2023;23:266.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

He J, Lan X, Liu X, Deng C, et al. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. BMC Cancer 2023;23:266.
PMID: 36959566